Table 2. Characteristics of studies on HBV load and recurrence of HCC.
| Author | Publication year | Study location | Treatment | No of cases | No of participants | Adjusted RR | 95% CI | Adjustment for covariates |
|---|---|---|---|---|---|---|---|---|
| Jang | 2007 | Korea | TACE | 32 | 62 | 3.77 | 1.70–8.38 | HBeAg status, Child-Pugh classification, No. of tumors, lamivudine use |
| Kim | 2008 | Korea | Resection | 75 | 157 | 1.61 | 1.01–2.55 | Tumor size, tumor number, vascular invasion, and grades |
| Chuma | 2009 | Japan | Resection or RFA | 38 | 64 | 2.67 | 1.31–5.47 | Gender, age, HBeAg status, ALT, Platelet count, PT, Albumin, Bilirubin, Liver fibrosis, tumor differentiation, AFP, PIVKA-II, tumor size tumor number initial treatment |
| Wu | 2009 | Taiwan | Resection | 39 | 92 | 2.55 | 1.04–6.24 | Ishak activity, multinodularity, ICG-15 |
| Qu | 2010 | China | Resection | 183 | 317 | 2.11 | 1.48–3.00 | Alpha-fetoprotein, microvascular, invasion, postoperative IFN-α treatment |
| Liang | 2010 | China | Resection | 38 | 64 | 1.80 | 0.80–4.11 | None |
| An | 2010 | Korea | Resection | 95 | 188 | 1.80 | 0.85–3.80 | ALT, Child-Pugh class B, HBeAg seropositivity, vascular invasion, cirrhosis, tumor size |
| Goto | 2011 | Japan | RFA | 42 | 69 | 2.67 | 1.16–6.14 | Albumin, Platelet count, prothrombin activity, Child-Pugh Class, number of nodules |
| Chung | 2011 | Korea | Local ablation | 63 | 140 | 1.02 | 0.61–1.71 | None |
| Li | 2011 | China | OLT | 43 | 148 | 2.45 | 1.10–5.45 | Age, gender, number of nodules, the largest nodule size, exceeding Milan criteria, vascular invasion, tumor differentiation, preoperative serum AFP level, HBV recurrence |
| Xia | 2012 | China | RFA | 67 | 152 | 1.73 | 0.88–3.40 | None |
| Mathews | 2012 | Korea | Resection | 99 | 247 | 1.01 | 0.50–2.02 | Age, gender, serum AFP, serum ALT, advanced MELD score, tumor size, microvascular invasion, advanced CLIP stage, E-S grade |
| Su | 2013 | Taiwan | Resection | 208 | 333 | 1.43 | 1.05–1.95 | GGT, macroscopic venous invasion, microscopic venous invasion |
| Kim | 2014 | Korea | RFA | 70 | 300 | 1.55 | 0.79–3.03 | None |
| Sohn | 2014 | Korea | RFA | 89 | 170 | 1.57 | 1.02–2.41 | Multinodularity, BCLC stage |
| Sohn | 2014 | Korea | Resection | 61 | 188 | 2.77 | 1.62–4.73 | Age, sex, Platelet, ALT, AFP, DCP, HBeAg, |
| Hung | 2016 | Hong Kong | Resection | 100 | 200 | 1.67 | 1.09–2.57 | AFP, tumor size, antiviral treatment, tumor differentiation, lymphovascular permeation, microsatellite lesions |
Abbreviations: HBV, hepatitis B virus; HCC, hepatocellular carcinoma; RR, relative risk; CI, confidence interval; TACE, transarterial chemolipiodoization, HBeAg, hepatitis B e antigen; AFP, alpha-fetoprotein; RFA, radiofrequency ablation; ALT, alanine aminotranferase; PT, prothrombin time; PIVKA-II, protein induced by vitamin K absence or antagonist II; ICG-15, indocyanine green 15-min retention rate; OLT, orthotopic liver transplantation; MELD, Model for End-Stage Liver Disease; BCP, basal core promoter; CLIP, Cancer of the Liver Italian Program; E-S grade, Edmondson-Steiner grade; GGT, γ-glutamyl transpeptidase; BCLC, Barcelona Clinic Liver Cancer; DCP, des-γ-carboxy prothrombin.